McGill University Health Centre

Running trials

• Not yet recruiting

  RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

  NCT07625930· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Not yet recruiting

  Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement

  NCT07877298· University Hospital Muenster· Source

• Recruiting

  Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

  NCT07282210· Phase 2· Biossil Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  The CANadian EXAcerbation of COPD Trial

  NCT07850648· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy

  NCT07634237· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

  NCT07284511· Phase 2/3· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT07571200· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

  NCT07483658· CHU de Quebec-Universite Laval· Source

• Recruiting

  Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation

  NCT04823299· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.

  NCT07739784· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

  NCT07309614· Phase 3· Université de Sherbrooke· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

  NCT07094048· Phase 4· CHU de Quebec-Universite Laval· Source

• Recruiting

  Evaluating the Feasibility of elleFA App Implementation

  NCT06452407· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough

  NCT06858748· McMaster University· Source

• Not yet recruiting

  A Patient Portal and PROMs to Improve Health Problem Detection and Retention in HIV Care: The DRHIVe Study

  NCT06928961· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Not yet recruiting

  REDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention

  NCT07245147· Jacqueline Joza· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Helping Couples Communicate Better: Does This Help Persons With Type 2 Diabetes Respond Better to a Step Count Prescription?

  NCT07142512· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  NCT07090499· Phase 1· Pfizer· Source

• Recruiting

  A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

  NCT07112339· Phase 4· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia

  NCT06816368· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

  NCT06337838· Phase 3· Hamilton Health Sciences Corporation· Source

• Recruiting

  COgnitioN With VERiciGuat Evaluation in Heart Failure

  NCT06601465· Phase 2· University of Alberta· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Predicting Acute Exacerbations of COPD Using Wearable Devices and Remote Monitoring Technology With AI/ML Models

  NCT06802003· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Enrolling by invitation

  Whole Heart Radiotherapy for End-stage Heart Failure

  NCT06299176· Phase 1· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT06665165· Phase 1· Amylyx Pharmaceuticals Inc.· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

  NCT06453486· Phase 2· University Health Network, Toronto· Source

• Recruiting

  Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

  NCT05272826· Phase 2· Canadian Myeloma Research Group· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  NCT06534983· Phase 2· Hoffmann-La Roche· Source

Showing 50 of 179.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Pancreatic cancer6 recruiting
• Bladder cancer5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Chronic kidney disease4 recruiting
• Colorectal cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Multiple myeloma4 recruiting
• Ovarian cancer4 recruiting
• Triple-negative breast cancer4 recruiting
• ALS (motor neurone disease)3 recruiting
• Asthma3 recruiting
• COPD3 recruiting
• Type 1 diabetes3 recruiting
• Type 2 diabetes3 recruiting
• Atrial fibrillation2 recruiting
• Childhood cancers2 recruiting
• Congenital heart disease2 recruiting
• Coronary artery disease2 recruiting
• Endometrial cancer2 recruiting
• Endometriosis2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Liver cirrhosis2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Dilated cardiomyopathy1 recruiting
• Friedreich ataxia1 recruiting
• Glaucoma1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Myocarditis1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Sarcoidosis1 recruiting
• Sickle cell disease1 recruiting
• Tuberculosis1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Assessing Optimal Inhaler Strategies During Acute Exacerbations of COPD (AECOPDs) Using Oscillometry

  NCT06495047· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  The Effects of Oscillatory Positive Expiratory Pressure (OPEP) Therapy in Patients With COPD

  NCT06614959· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Withdrawn

  Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia

  NCT06560346· Friedreich's Ataxia Research Alliance· Source

• Recruiting

  A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

  NCT06810505· Phase 3· AbbVie· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Withdrawn

  Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids

  NCT05568940· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Terminated

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

  NCT06524739· Phase 3· CSL Behring· Source

• Terminated

  A Study of SGN-MesoC2 in Advanced Solid Tumors

  NCT06466187· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Oral Supplementation During PR Participation in COPD

  NCT06324214· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  NCT06272981· Biosense Webster, Inc.· Source

• Completed

  A Multimodal Wearable Platform for Heart Failure Disease Stratification

  NCT06335264· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Completed

  Patient Perspective on Climate Impact of Inhalers

  NCT06097507· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

  NCT05813275· Phase 3· Apnimed· Source

• Completed

  A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator

  NCT05971693· Biosense Webster, Inc.· Source

• Completed

  Measuring Lung Mechanics in Patients with COPD Using the REOM Handheld Portable Device

  NCT05913323· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

  NCT05860296· Phase 1/2· SignalChem Lifesciences Corporation· Source

• Completed

  A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

  NCT05571137· Takeda· Source

• Completed

  Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  NCT05118893· Anthony Tang· Source

• Recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

  NCT05711394· Phase 3· AbbVie· Source

• Completed

  Wearable Devices in the Recovery Phase of Acute Exacerbations of COPD (AECOPDs)

  NCT05776654· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  Multifaceted Intervention Using Telehealth to Reduce the Risk of Falls and Fractures in Older Men

  NCT05927623· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Safety and Efficacy of Canagliflozin in Advanced CKD

  NCT05309785· Phase 4· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Letermovir in ART-treated HIV-infected Persons

  NCT05362916· Jean-Pierre Routy· Source

• Completed

  IBD Neoplasia Surveillance RCT

  NCT05809999· Ottawa Hospital Research Institute· Source

• Completed

  ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES

  NCT05280067· Phase 2· Zetagen Therapeutics, Inc· Source

• Terminated

  Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

  NCT04638582· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  DECIDE-CV Using AI

  NCT05482958· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Completed

  Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

  NCT05180240· Phase 2· Cardiol Therapeutics Inc.· Source

• Completed

  Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

  NCT05446870· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  Prehabilitation for Patients Awaiting Liver Transplantation

  NCT05237583· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Terminated

  Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease

  NCT05049525· Phase 2· Montreal Heart Institute· Source

• Terminated

  Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  NCT05070845· Phase 2· Pfizer· Source

• Completed

  Keeping in Touch (KiT) With Youth as They Transition to Adult Type 1 Diabetes Care

  NCT05434754· The Hospital for Sick Children· Source

• Completed

  A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

  NCT05143957· Phase 2· Ionis Pharmaceuticals, Inc.· Source

• Completed

  EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement

  NCT05118308· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Hoffmann-La Roche· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

Showing 50 of 99.

Conditions

Diseases this institution publishes on or runs trials for.

• HIV66 works · 7 trials
• Crohn's disease44 works · 2 trials
• Ovarian cancer41 works · 16 trials
• Ulcerative colitis39 works · 1 trial
• Endometrial cancer38 works · 10 trials
• Lupus (SLE)25 works · 1 trial
• Cervical cancer25 works · 3 trials
• COPD24 works · 9 trials
• Type 1 diabetes22 works · 8 trials
• Sarcoma20 works · 7 trials
• Aortic stenosis15 works · 1 trial
• Hepatitis C14 works · 0 trials
• Systemic sclerosis (scleroderma)13 works · 0 trials
• Familial hypercholesterolaemia12 works · 0 trials
• Duchenne muscular dystrophy11 works · 0 trials
• Psoriatic arthritis10 works · 0 trials
• Polycystic kidney disease7 works · 1 trial
• ANCA-associated vasculitis5 works · 0 trials